Trial · NCT02145468
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Up to 12 weeks | Intent-To-Treat (ITT) Population. ITT population comprised of all randomized participants. | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of MACE Through Week 24 | Up to Week 24 | ITT Population. | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Week 12 and Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death, MI or Hospitalization for Heart Failure (HF) up to Week 12 and Week 24. | Week 12 and Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Expanded Composite of Arterial CV Events Defined as CV Death, MI, SRI-UR or Stroke Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of Coronary Events Defined as CHD Death, MI, SRI-UR or Any Unplanned Coronary Artery Revascularization Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death or Hospitalization for HF Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death, MI or Stroke Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Expanded Composite of CV Death, MI, SRI-UR, Stroke or Hospitalization for HF Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CHD Death, MI or SRI-UR Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CHD Death or MI Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of All-cause Death, MI or SRI-UR Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of All-cause Death or MI Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death, Type I (Spontaneous) MI or SRI-UR Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death or Type I (Spontaneous) MI Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of Definite or Probable Stent Thrombosis Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X, in the category titles). | Participants | NUMBER |
| SECONDARY | Number of Participants Re-hospitalized Within 30 Days of Discharge | Within up to 30 days of post discharge | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With All-cause Mortality Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With CV Death Events Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With CHD Death Events Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02145468/outcomes